| Health / Medical Topics |
Transforming Growth Factor-Beta Superfamily Inhibitor ACE-536
A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked to the human IgG1 Fc domain, with red blood cell stimulating activity. Upon subcutaneous administration, ACE-536 inhibits several ligands in the transforming growth factor (TGF)-beta superfamily. This prevents activation of a variety of TGF-beta superfamily members involved in late stage erythropoiesis and results in an increased differentiation and proliferation of erythroid progenitors. ACE-536 acts at a different, later stage than erythropoietin. This agent ultimately enhances red blood cell production and prevents anemia. (NCI Thesaurus)
YOU MAY ALSO LIKE
Factor synthesized in a wide variety of tissues including platelets, placenta, and both normal and transformed cell lines. It acts synergistically with…
Expressed in a variety of tissues, Transforming Growth Factor-Beta Family Genes encode Transforming Growth Factor-Beta, an autocrine growth factor that can act…
Transforming growth factor beta-3 (412 aa, ~47 kDa) is encoded by the human TGFB3 gene. This protein is involved in cell proliferation,…
Transforming growth factor beta-2 (414 aa, ~48 kDa) is encoded by the human TGFB2 gene. This protein plays a role in cell…
Transforming growth factor beta-1 (390 aa, ~44 kDa) is encoded by the human TGFB1 gene. This protein is involved in cell proliferation,…
Transforming growth factor beta receptor type 3 (851 aa, ~93 kDa) is encoded by the human TGFBR3 gene. This protein is involved…
